Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

10
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

18
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
18
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

18.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.6K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.0K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.0K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

10
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
10
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

655
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
655

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of galectin-3 in systemic lupus erythematosus: A systematic review and meta-analysis.

Lupus·2026
Same author

An Observational Case-Control Study of the Anti-Inflammatory Effects of Bromelain on Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus.

Mediterranean journal of rheumatology·2026
Same author

Association of ABO Blood Group and Severe Plasmodium falciparum Malaria: An Updated Meta-Analysis and Trial Sequential Analysis.

Tropical medicine & international health : TM & IH·2026
Same author

Methodological Concerns in TNFAIP3, IRAK1, and TLR4 Polymorphism Analysis for RA Susceptibility.

Immunity, inflammation and disease·2026
Same author

Efficacy of total antioxidant capacity as biomarker of oxidative stress in response to organochlorine pesticide exposure.

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals·2026
Same author

Meta-analysis reveals apolipoprotein ε4 confers higher susceptibility to Parkinson's disease dementia in Asian populations.

Frontiers in aging neuroscience·2026

Related Experiment Video

Updated: Feb 17, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K

MIF -173 G > C (rs755622) Gene Polymorphism Modulates Tuberculosis Risk: Evidence from a Meta-analysis and Trial

Mohammed Y Areeshi1, Raju K Mandal1, Sajad A Dar1,2

  • 1Research and Scientific Studies Unit, College of Nursing & Allied Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia.

Scientific Reports
|December 7, 2017
PubMed
Summary
This summary is machine-generated.

The macrophage migration inhibitory factor (MIF) -173 G>C gene variant increases tuberculosis (TB) risk. This meta-analysis confirms MIF -173 G>C as a significant risk factor for TB, particularly in Asian populations.

More Related Videos

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
07:35

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Published on: April 25, 2014

13.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K

Related Experiment Videos

Last Updated: Feb 17, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K
Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
07:35

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Published on: April 25, 2014

13.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K

Area of Science:

  • Immunogenetics
  • Molecular Epidemiology

Background:

  • Macrophage migration inhibitory factor (MIF) is crucial for immune responses against Mycobacterium tuberculosis (M.tb).
  • The MIF -173 G>C gene polymorphism is investigated for its potential role in tuberculosis (TB) susceptibility.
  • Previous studies on this polymorphism and TB risk yielded inconclusive results.

Purpose of the Study:

  • To conduct a meta-analysis to precisely determine the association between the MIF -173 G>C polymorphism and TB risk.
  • To evaluate the overall risk and specific genetic models associated with this polymorphism.
  • To investigate potential ethnic variations in the association.

Main Methods:

  • A systematic literature search was conducted across Google Scholar, PubMed, and EMBASE databases.
  • Six eligible studies investigating the MIF -173 G>C polymorphism and TB risk were included.
  • Meta-analysis was performed using four genetic models: allelic, homozygous, heterozygous, and dominant.

Main Results:

  • The meta-analysis revealed a significant association between the MIF -173 G>C polymorphism and increased TB risk across all four genetic models.
  • Specifically, the allelic (C vs. G), homozygous (CC vs. GG), heterozygous (GC vs. GG), and dominant (CC+GC vs. GG) models showed increased risk (ORs ranging from 1.517 to 1.631).
  • Subgroup analysis indicated a higher TB risk in populations of Asian ethnicity. No publication bias was detected.

Conclusions:

  • The MIF -173 G>C gene variant is a significant risk factor for tuberculosis susceptibility.
  • This polymorphism serves as a potential prognostic marker for TB.
  • The findings are particularly relevant for Asian populations, highlighting ethnic-specific genetic influences on TB risk.